cAMPfield Launches With $180 Million Series A to Advance Prifemilast, a Potential Best-in-Class Oral Therapy for IBD
Oral PDE4 inhibitors have demonstrated efficacy in Phase 2 studies of ulcerative colitis cAMPfield's lead candidate is prifemilast, a potentially best-in-class PDE4 inhibitor for the treatment of IBD, in-licensed from Newsoara Biopharma Co., Ltd. (Newsoara) Founded by Mountainfield...
Oral PDE4 inhibitors have demonstrated efficacy in Phase 2 studies of ulcerative colitis cAMPfield's lead candidate is prifemilast, a potentially best-in-class PDE4 inhibitor for the treatment of IBD, in-licensed from Newsoara Biopharma Co., Ltd. (Newsoara) Founded by Mountainfield...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.